Phenethyl Isothiocyanate Exhibits Antileukemic Activity \u3cem\u3eIn Vitro\u3c/em\u3e and \u3cem\u3eIn Vivo\u3c/em\u3e by Inactivation of Akt and Activation of JNK Pathways by Gao, N. et al.
University of Kentucky
UKnowledge
Toxicology and Cancer Biology Faculty
Publications Toxicology and Cancer Biology
4-7-2011
Phenethyl Isothiocyanate Exhibits Antileukemic
Activity In Vitro and In Vivo by Inactivation of Akt
and Activation of JNK Pathways
N. Gao
University of Kentucky
Amit Budhraja
University of Kentucky, amit.budhraja@uky.edu
S. Cheng
University of Kentucky
E.-H. Liu
III Military Medical University, China
J. Chen
III Military Medical University, China
See next page for additional authors
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/toxicology_facpub
Part of the Medical Toxicology Commons
This Article is brought to you for free and open access by the Toxicology and Cancer Biology at UKnowledge. It has been accepted for inclusion in
Toxicology and Cancer Biology Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact
UKnowledge@lsv.uky.edu.
Repository Citation
Gao, N.; Budhraja, Amit; Cheng, S.; Liu, E.-H.; Chen, J.; Yang, Z.; Chen, D.; Zhang, Zhuo; and Shi, Xianglin, "Phenethyl
Isothiocyanate Exhibits Antileukemic Activity In Vitro and In Vivo by Inactivation of Akt and Activation of JNK Pathways" (2011).
Toxicology and Cancer Biology Faculty Publications. 33.
https://uknowledge.uky.edu/toxicology_facpub/33
Authors
N. Gao, Amit Budhraja, S. Cheng, E.-H. Liu, J. Chen, Z. Yang, D. Chen, Zhuo Zhang, and Xianglin Shi
Phenethyl Isothiocyanate Exhibits Antileukemic Activity In Vitro and In Vivo by Inactivation of Akt and Activation
of JNK Pathways
Notes/Citation Information
Published in Cell Death and Disease, v. 2, e140, p. 1-9.
Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed
under a Creative Commons Attribution-NonCommercial-NoDerivative Works 3.0 Unported License. To
view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
Digital Object Identifier (DOI)
http://dx.doi.org/10.1038/cddis.2011.22
This article is available at UKnowledge: https://uknowledge.uky.edu/toxicology_facpub/33
Phenethyl isothiocyanate exhibits antileukemic
activity in vitro and in vivo by inactivation of Akt
and activation of JNK pathways
N Gao*,1,2, A Budhraja2, S Cheng2, E-H Liu1, J Chen3, Z Yang3, D Chen1, Z Zhang2 and X Shi*,2
Effects of phenethyl isothiocyanate (PEITC) have been investigated in human leukemia cells (U937, Jurkat, and HL-60) as well as
in primary human acute myeloid leukemia (AML) cells in relation to apoptosis and cell signaling events. Exposure of cells to
PEITC resulted in pronounced increase in the activation of caspase-3, -8, -9, cleavage/degradation of PARP, and apoptosis in
dose- and time-dependent manners. These events were accompanied by the caspase-independent downregulation of Mcl-1,
inactivation of Akt, as well as activation of Jun N-terminal kinase (JNK). Inhibition of PI3K/Akt by LY294002 significantly
enhanced PEITC-induced apoptosis. Conversely, enforced activation of Akt by a constitutively active Akt construct markedly
abrogated PEITC-mediated JNK activation, Mcl-1 downregulation, caspase activation, and apoptosis, and also interruption of the
JNK pathway by pharmacological or genetically (e.g., siRNA) attenuated PEITC-induced apoptosis. Finally, administration of
PEITC markedly inhibited tumor growth and induced apoptosis in U937 xenograft model in association with inactivation of Akt,
activation of JNK, as well as downregulation of Mcl-1. Taken together, these findings represent a novel mechanism by which
agents targeting Akt/JNK/Mcl-1 pathway potentiate PEITC lethality in transformed and primary human leukemia cells and
inhibitory activity of tumor growth of U937 xenograft model.
Cell Death and Disease (2011) 2, e140; doi:10.1038/cddis.2011.22; published online 7 April 2011
Subject Category: Cancer
Epidemiological studies support the evidence that the con-
sumption of cruciferous vegetables has long been associated
with a reduced risk in the occurrence of cancer at various
sites, including the prostate, lung, breast, and colon.1 The
anticarcinogenic effect of cruciferous vegetables is attributed
to organic isothiocyanates (ITCs), which are present in a
variety of edible cruciferous vegetables such as broccoli,
watercress, cabbage, and so on.1 Phenethyl isothiocyanate
(PEITC) is one of the ITC family of compounds that
has attracted a great deal of attention owing to its
remarkable cancer chemopreventive activity.2 For
example, PEITC administration has been shown to significantly
inhibit 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-in-
duced pulmonary neoplasia in rats and mice,3,4 N-nitroso-
benzylmethylamine-induced esophageal cancer in rats,5 and
benzo[a]pyrene-induced carcinogenesis in mice.6 A possible
mechanism by which PEITC protects against cancer is
through cell cycle arrest and apoptosis.7 Therefore, an
understanding of the mechanism of PEITC-related lethality
is important for its further development as a clinically
useful chemopreventive or therapeutic agent because this
knowledge could lead to the identification of mechanism-
based biomarkers potentially useful in future clinical trials.
Recent studies have shown that PEITC is a strong inducer
of apoptosis in various cancer cell types. Xiao et al.8 have
shown that PEITC-induced apoptosis involved extracellular
signal-regulated kinase (ERK) activation and the cleavage of
procaspase-3, procaspase-8, and procaspase-9 in PC-3
cells. Chen et al.9 have reported that apoptosis induction by
PEITC is in association with sustained activation of c-Jun
NH2-terminal kinase in Jurkat cells. Huang et al.10 provided
convincing evidence to suggest an essential role for p53 in
apoptosis induction by PEITC. More recent studies have
indicated that PEITC-induced cell death involves mitochondria
-mediated activation of caspase cascade and generation of
reactive oxygen species (ROS).11,12 Previous studies have
shown that PEITC inhibited growth and induced apoptosis of
human leukemia (HL-60) cells, and glutathione metabolism
may be involved in PEITC-related lethality.13 However, the
molecular mechanisms of PEITC-induced apoptosis in human
leukemia cells are not fully defined. There is no available
information concerning PEITC’s in vivo efficacy against
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leukemia. This study provides experimental evidence to
indicate, for the first time, that the cell death caused by
PEITC is initiated by the inactivation of Akt, leading, in turn, to
Jun N-terminal kinase (JNK) activation, and culminating in
Mcl-1 downregulation. In addition, we show that administra-
tion of PEITC significantly inhibits the tumor growth of U937
xenografts in SCIDmice in association with inactivation of Akt,
activation of JNK, as well as induction of apoptosis.
Results
PEITC induces apoptosis, caspase activation, and PARP
cleavage in U937 human leukemia cells in dose- and
time-dependent manners. A dose-dependent study of
U937 cells exposed to various concentrations of PEITC for
3 and 6h was shown in Figure 1a; modest degrees of
apoptosis were noted at 4 mM PEITC concentration, which
increased substantially at concentration of 6 mM. These
events became very extensive at concentration of 8 mM. A
time-course study of cells exposed to 8 mM PEITC revealed a
significant increase in apoptosis as early as 3 h, and reached
near-maximal levels after 6 h of drug exposure (Figure 1b).
Consistent with these results, exposure of cells to 4mM
PEITC for 3 and 6 h revealed a moderate increase in
cleavage/activation of caspase-3, -8, and -9, as well as PARP
degradation and a marked increase at concentrationsZ6mM
(Figure 1c). Time-course study of cells exposed to 8mM
PEITC revealed moderate increases in cleavage/activation of
caspase-3, -8, and -9, as well as PARP degradation 2 or 3 h
after drug exposure. These events became apparent at 4 h,
and reached near-maximal levels at 6 h after drug exposure
(Figure 1d).
Exposure of U937 cells to PEITC results in rapid
decrease in Mcl-1 protein level. To understand the
critical roles of Bcl-2 family proteins have in apoptosis,
expression of these proteins in U937 cells was monitored
following treatment with PEITC. As shown in Figure 2a,
exposure of cells to 4mM PEITC for 3 and 6 h resulted in
moderate decrease in the expression of Mcl-1. These events
became apparent at 6 mM and very extensive at 8 mM after
drug exposure. A time-course study showed that exposure of
U937 cells to 8 mM PEITC resulted in modest decrease in the
expression of Mcl-1 as early as 2 h after drug exposure.
These events became apparent at 3 h and very extensive
at 4 h after drug exposure (Figure 2b). In contrast, the
expression of other Bcl-2 family proteins such as XIAP, Bcl-2,
Bcl-xL, Bax, and Bad remained unaffected (Figures 2a and
b). Taken together, these findings show that downregulation
of Mcl-1 may be responsible for PEITC lethality in U937 cells.
Exposure of U937 cells to PEITC results in marked
decrease in levels of phospho-Akt and significant
increase in the expression of phospho-JNK. Effects
of PEITC on various signal-transduction pathways
implicated in apoptosis regulation were also investigated.
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Figure 1 Phenethyl isothiocyanate (PEITC) significantly induces apoptosis,
caspase activation, and poly(ADP-ribose) polymerase (PARP) cleavage in U937
human leukemia cells in dose- and time-dependent manners. (a) U937 cells were
treated without or with various concentrations of PEITC as indicated for 3 and 6 h.
(b) U937cell were treated without or with 8 mM PEITC for 1, 3, 6, 9, 12, and 24 h.
Cells were stained with Annexin V/propidium iodide (PI), and apoptosis was
determined using flow cytometry as described in Materials and Methods. (c) U937
cells were treated without or with various concentrations of PEITC as indicated for 3
and 6 h. (d) U937 cells were treated without or with 8mM PEITC for 0.5, 1, 2, 3, 4, 6,
12, and 24 h. After treatment of U937 cells with the indicated PEITC concentration
or the indicated time interval, total cellular extracts were prepared and subjected to
western blot assay using antibodies against PARP, cleaved-caspase-3
(C-Caspase-3), caspase-8, and cleaved-caspase-9 (C-Caspase-9). Each lane
was loaded with 30mg protein. Blots were subsequently stripped and reprobed with
antibody against b-actin to ensure equivalent loading and transfer. Two additional
studies yielded equivalent results
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Figure 2 Phenethyl isothiocyanate (PEITC) induces downregulation of Mcl-1,
inactivation of Akt, and activation of Jun N-terminal kinase (JNK) in U937 cells.
(a) U937 cells were treated without or with the indicated concentrations of PEITC for
3 and 6 h. (b) U937 cells were treated without or with 8 mM PEITC for 0.5, 1, 2, 3, 4,
6, 12, and 24 h. Total cellular extract were prepared and subjected to western blot
analysis using antibody against XIAP, Mcl-1, Bcl-2, Bcl-xL, Bax, and Bad. (c) U937
cells were treated without or with the indicated concentrations of PEITC for 3 and
6 h. (d) U937 cells were treated without or with 8 mM PEITC for 0.5, 1, 2, 3, 4, 6, 12,
and 24 h. Total cellular extract were prepared and subjected to western blot analysis
using antibodies against cell signaling molecules, including phospho-Akt, Akt,
phospho-JNK, and JNK. Each lane was loaded with 30 mg protein. Blots were
subsequently stripped and reprobed with antibody against b-actin to ensure
equivalent loading and transfer. Two additional studies yielded equivalent results
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Dose-dependent study indicated that exposure of U937 cells
to PEITC at 2 mM resulted in a slight reduction in levels of
phospho-Akt (Ser473). These events became apparent at
concentration of 4 and 6 mM. The complete blockage of levels
of phospho-Akt (Ser473) was noted after drug exposure at
8mM (Figure 2c). However, PEITC had little or no significant
effects on total Akt. In addition, treatment of cells with PEITC
resulted in a dramatic increase in levels of phospho-JNK, but
had no effect on levels of total JNK. A time-course study
showed that exposure of U937 cells to 8mM PEITC resulted
in modest decrease in levels of phospho-Akt and a increase
in the activation of JNK as early as 2 h after drug exposure.
These events became apparent at 4 and 6h and reached
near-maximal effects at 12 or 24 h (Figure 2d). In contrast,
PEITC had little or no effect on expression of total or
phospho-mTOR, phospho-ERK, and phospho-p38 (data not
shown). These results suggest that a pronounced
inactivation of Akt and an activation of JNK may have
important roles in PEITC-induced apoptosis in U937 human
leukemia cells.
PEITC has similar effects on apoptosis in multiple
human leukemia cell types and primary AML
blasts. Various human leukemia cell types, including U937
myelomonocytic, HL-60 promyelocytic, and Jurkat
T-lymphoblastic leukemic cells, were exposed to 8mM PEITC
for 6 h, after which apoptosis was determined by Annexin
V/PI analysis. As shown in Figure 3a, treatment with PEITC
resulted in dramatic increase in apoptosis in these cell lines.
Consistent with these results, exposure of cells to PEITC
revealed significant increases in cleavage/activation of
caspase-3, -8, and -9, as well as PARP degradation
(Figure 3b). Similarly, exposure of various human leukemia
cells to PEITC resulted in marked decrease in expression of
Mcl-1 (Figure 3c). Comparable inactivation of Akt and
activation of JNK were also observed in these cell lines
after drug exposure (Figure 3d).
Furthermore, exposure of blasts from 17 patients with acute
myeloid leukemia (AML) to 8 mM PEITC for 24 h revealed
marked increase in cell death (Figure 3e), accompanied by
cleavage/activation of caspase-3, -8, and -9, as well as PARP
degradation (Figure 3f). In contrast, the PEITC regimen
exerted only minimal toxicity toward normal human peripheral
blood mononuclear cells (Figure 3g). Taken together, these
findings indicate that PEITC selectively triggers apoptosis in
multiple human leukemia cells lines as well as in primary AML
blasts, but displays significantly less toxicity toward normal
hematopoietic cells.
PEITC lethality is associated with the caspase-
independent inactivation of Akt and activation of
JNK. To assess whether PEITC-induced inactivation of Akt
and activation of JNK are dependent on caspases activation,
the pan-caspase inhibitor Z-VAD-FMK was used. Co-
treatment of cells with the caspase inhibitor Z-VAD-FMK,
which abrogated PEITC-induced apoptosis (Figure 4a),
caspase activation, and PARP degradation (Figure 4b),
failed to prevent Akt inactivation, JNK activation, as well as
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Figure 3 Phenethyl isothiocyanate (PEITC) had similar effects on apoptosis in other human leukemia cell lines as well as primary acute myeloid leukemia (AML) human
leukemia cells. U937, Jurkat, and HL-60 cells were treated without or with 8 mM PEITC for 6 h, (a) after which the percentage of apoptotic cells was determined by Annexin
V/propidium iodide (PI) staining and flow cytometry as described in Materials and Methods. The values obtained from Annexin V/PI assays represent the mean±standard
deviation (S.D.) for three separate experiments. **Values for cells treated with PEITC were significantly increased compared with values obtained for control by Student’s
t-test; Po0.01. Total cellular extracts were prepared and subjected to western blot analysis using antibodies against poly(ADP-ribose) polymerase (PARP), cleaved-caspase-
3 (C-Caspase-3), caspase-8, C-Caspase-9 (b), anti-apoptotic protein Mcl-1 (c), and cell signaling molecules including phospho-Akt, Akt, phospho-Jun N-terminal kinase
(JNK), and JNK (d). (e) Blasts from 17 patients with AML were isolated as described in Materials and Methods. After washing and counting, isolated mononuclear cells were
treated without or with 8mMPEITC for 24 h, after which the percentage of apoptotic cells was determined by Annexin V/PI staining and flow cytometry. (f) Total cellular extracts
of blasts from two AML patients (P1 and P6) were prepared and subjected to western blot analysis using antibodies against PARP, C-Caspase-3, caspase-8, and C-Caspase-
9. (g) Normal peripheral blood mononuclear cells were treated without or with 8 mM PEITC for 24 h, after which the percentage of apoptotic cells was determined by Annexin
V/PI staining and flow cytometry as described in Materials and Methods. The values represent the means±S.D. for three replicate determinations. For western blot analysis,
each lane was loaded with 30mg of protein; blots were subsequently stripped and reprobed with antibody against b-actin to ensure equivalent loading. Two additional studies
yielded equivalent results
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Mcl-1 downregulation induced by PEITC (Figures 4c and d).
Such findings indicate that inactivation of Akt, activation
of JNK, and downregulation of Mcl-1 mediated by PEITC do
not simply represent a secondary, caspase-dependent
event.
The effects of interruption of PI3K/Akt signaling pathway
on PEITC-induced apoptosis. To assess the effects of
interruption of the PI3K/Akt pathway on the lethal actions of
PEITC, U937 cells were exposed to sublethal concentration
of PEITC (i.e., 4mM;B25%) in the presence of PI3K inhibitor
LY294002 (i.e., 20 mM), after which apoptosis was assessed.
As shown in Figure 5a, co-administration of LY294002 with
PEITC resulted in a pronounced increase apoptosis in U937
cells (Po0.01 versus PEITC treatment alone). Similarly,
co-administration of PEITC and LY294002 at concentrations
that were ineffective or marginally effective by themselves
resulted in pronounced increase in the activation of caspase-
3, -8, and -9, and PARP degradation (Figure 5b). Combined
treatment with PEITC and LY294002 also resulted in
the potentiation of Mcl-1 downregulation (Figure 5c).
Furthermore, co-administration of PEITC and LY294002
essentially abrogated expression of the phosphorylated Akt
(Ser473) and potentiated activation of JNK (Figure 5d).
Because PEITC inhibits phosphorylation of Akt and functions
like Akt inhibitor, we used 4mM PEITC instead of 8mM.
To characterize the functional role of perturbations in Akt in
the apoptotic response of leukemia cells to PEITC, U937 cells
ectopically expressing constitutive active form of Akt (Akt-CA)
and the dominant-negative Akt (Akt-DN) were employed. As
shown in Figure 6a, exposure of pcDNA3.1 vector control cells
and Akt-DN cells to PEITC at a concentration of 8 mM for 6 h
resulted in significant increase in apoptosis. However,
apoptosis was strikingly attenuated in Akt constitutively active
cells after drug exposure. Consistent with these results, the
activation of caspases and cleavage of PARP were also
markedly attenuated in Akt-CA cells (Figure 6b). In addition,
enforced activation of Akt efficaciously blocked PEITC-
mediated Mcl-1 downregulation (Figure 6c). Western blot
analysis displayed marked increase in levels of total and
phospho-Akt in Akt-CA cells. PEITC failed to inhibit phos-
phorylation of Akt in these Akt cells (Figure 6d). Interestingly,
the ability of PEITC to induce JNK activation was essentially
abrogated in Akt-CA cells (Figure 6d). Taken together, these
findings indicate that inactivation of the Akt pathway has a
critical role in PEITC-related lethality and that this event lies
upstream of Mcl-1 downregulation and JNK activation.
Effects of pharmacological and genetic inhibition of JNK
on PEITC-related lethality. The functional role of JNK
activation in PEITC lethality was then investigated using both
pharmacological and genetic approaches. As shown in
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Figure 4 Phenethyl isothiocyanate (PEITC)-induced Mcl-1 downregulation, Akt
inactivation, and Jun N-terminal kinase (JNK) activation were not dependent
on caspase activation. U937 cells were pretreated with the caspase
inhibitor benzyloxycarbonyl-Val-Ala-Asp(O-methyl)-fluoromethylketone (Z-VAD-
FMK) (10mM) for 1 h, followed by treatment with 8 mM of PEITC for 3 and 6 h.
(a) Cells were stained with Annexin V/propidium iodide (PI). Apoptosis was
determined using flow cytometry as described in Materials and Methods. The values
obtained from Annexin V assays represent the means±standard deviation (S.D.)
for three separate experiment. **Values for cells treated with PEITC and Z-VAD-
FMK were significantly reduced compared with values obtained for PEITC alone by
Student’s t-test; Po0.01. Total protein extracts were prepared and subjected to
western blot assay using antibodies against apoptosis-related proteins, including
PARP, cleaved-caspase-3 (C-Caspase-3), caspase-8, and C-Caspase-9
(b); antiapoptotic protein Mcl-1 (c); as well as cell signaling proteins, including
phospho-Akt, Akt, phospho-JNK, and JNK (d). For western blot analysis, each lane
was loaded with 30mg of protein, and blots were subsequently stripped and
reprobed with antibody against b-actin to ensure equivalent loading
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Figure 5 Inhibition of phosphoinositide 3-kinase (PI3K)/Akt by LY294002 (LY)
enhanced phenethyl isothiocyanate (PEITC)-induced apoptosis in human leukemia
cells. U937 cells were pretreated with 20mM of LY for 1 h, followed by the addition of
4mM of PEITC for 3 and 6 h. (a) Cells were stained with Annexin V/propidium iodide
(PI), and apoptosis was determined using flow cytometry as described in Materials
and Methods. The values obtained from Annexin V/PI assays represent the
means±standard deviation (S.D.) for three separate experiments. **Values for
cells treated with PEITC and LY in combination were significantly greater than those
for cells treated with PEITC alone by Student’s t-test; Po0.01. Total cellular
extracts were prepared as described in Materials and Methods, and subjected to
western blot analysis using antibodies against apoptosis-related proteins, including
poly(ADP-ribose) polymerase (PARP), cleaved-caspase-3 (C-Caspase-3),
caspase-8, and C-Caspase-9 (b), antiapoptotic protein Mcl-1 (c), and cell signaling
molecules, including phospho-Akt, Akt, phospho-Jun N-terminal kinase (JNK), and
JNK (d). For western blot assay, each lane was loaded with 30mg of protein; blots
were subsequently stripped and reprobed with antibody against b-actin to ensure
equivalent loading. Two additional studies yielded equivalent results
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Figure 7a, co-administration of a non-toxic concentration of
SP600125 (i.e., 10 mM) with a toxic concentration of PEITC
(8mM; B75% for 6 h) resulted in a pronounced decrease in
apoptosis (i.e., to B30%). Consistently, co-administration of
SP600125 also markedly attenuated PEITC-mediated
caspases activation and PARP degradation (Figure 7b).
Co-administration of SP600125 also attenuated PEITC-
induced Mcl-1 downregulation and JNK activation (Figures
7c and d). As SP600125 is not completely specific for JNK,14
a genetic approach utilizing JNK1 siRNA was employed. As
shown in Figure 7f, transient transfection of U937 cells with
JNK1 siRNA reduced the expression of JNK1 to 50%
compared with control cells, and resulted in a significant
reduction in PEITC-mediated apoptosis (Po0.01 versus
control siRNA cells). Taken together, these findings
indicate that JNK activation has an important functional role
in PEITC-related lethality.
PEITC inhibits tumor growth of U937 xenograft model
accompanied by striking induction of apoptosis,
inactivation of Akt, and activation of JNK. To assess
whether our in vitro observations could be translated into an
animal model system, NOD/SCID mice were inoculated
intraperitoneally (i.p.) with U937 cells, after which mice
received injections with vehicle or PEITC (50mg/kg, i.p.) for
20 days starting 3 days after the injection of U937 human
leukemia cells. As shown in Figure 8a, treatment with PEITC
resulted in a modest, but significant suppression of tumor
growth 10 days following drug exposure (Po0.05 versus
vehicle control). These events became more apparent
15 and 20 days after drug exposure (Po0.01 between
PEITC treatment and vehicle control). In contrast, no
statistically significant change in body weight was noted
comparing vehicle control and PEITC regimen (Figure 8b).
Moreover, the mice of PEITC group did not exhibit any other
signs of toxicity such as agitation, impaired movement and
posture, indigestion or diarrhea, and areas of redness or
swelling. These results indicated that PEITC administration
significantly inhibited tumor growth of U937 xenograft without
causing any side effects and/or toxicity to the mice.
The morphological changes and induction of apoptosis in
U937 cells in vivo were investigated using hematoxylin and
eosin (H&E) staining and TUNEL assay. As shown in
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Figure 7 Effects of pharmacological and genetic interruption of Jun N-terminal
kinase (JNK) on phenethyl isothiocyanate (PEITC)-induced apoptosis. U937 cells
were pretreated with 10mM of JNK inhibitor, SP600125 (SP), for 1 h, followed by the
addition of 8 mM of PEITC for 3 and 6 h. (a) Cells were stained with Annexin V/PI,
and apoptosis was determined using flow cytometry as described in Materials and
Methods. The values obtained from Annexin V/PI assays represent the
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PEITC after transfection with JNK1 siRNA oligonucleotides were significantly
decreased compared with those for control cells treated with PEITC by Student’s
t-test; Po0.01
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Figure 8c, the sections of U937 xenografts from mice treated
with PEITC exhibited a reduced number of cancer cells, with
signs of necrosis with infiltration of inflammatory cells (i.e.,
phagocytic cells), fibrosis, as well as apoptotic regions,
identified by their amorphous shape and condensed nuclei.
Moreover, exposure to PEITC resulted in a striking induction
of apoptosis in tumor cells, with signs of numerous dark
brown-colored apoptotic cells. Also, exposure to PEITC
caused a rapid increase in immunoreactivity for the cleaved
form of PARP and caspase-3, indicative of apoptosis.
The preceding findings implied that downregulation of
Mcl-1, inactivation of Akt, and activation of JNK might have
important roles in PEITC-mediated lethality in U937 cells
in vitro. To evaluate whether the preceding in vitro findings
would be operative in vivo, immunohistochemistry analysis
was performed to evaluate the expression of Mcl-1, phospho-
Akt, and phospho-JNK in tissue sections of U937 xenografts.
As shown in Figure 8d, immunostaining of tumors from mice
treated with PEITC showed that the levels of Mcl-1 and
phospho-Akt were decreased and phospho-JNK was
increased. Collectively, these findings suggest that disruption
of Akt/JNK/Mcl-1 signaling may also contribute to lethality
induced by PEITC in vivo.
Discussion
These results indicate that PEITCmarkedly induces cell death
in multiple human leukemia cell types and primary human
AML blast cells. Our results also provide detailed molecular
mechanistic information as to how PEITC exerts its apoptotic
effects on human leukemia cells (i.e., by inactivation of Akt,
activation of JNK, and downregulation of Mcl-1). Previous
studies indicated that PEITC was shown to induce apoptosis
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The sections were lightly counterstained with hematoxylin and photographed with a Scan Scope. Original magnification  400
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in many cancer cells such as prostate,8,11 breast,15 lung,16
hepatoma,17 colon,18 as well as leukemia.13 Mechanism of
PEITC-induced apoptosis is not fully understood, but known
cellular responses to this promising agent include ERK,8
JNK,9 nuclear factor-kB (NF-kB),19 and ROS-mediated
apoptosis induction.11,12 Presently, little information is avail-
able concerning the functional role of the Akt pathway in
mediating PEITC-induced lethality, particularly in malignant
hematopoietic cells. The results of this study show that Akt
inactivation not only represents the primary cause, but also
have an important functional contribution in JNK activation,
Mcl-1 downregulation, and lethality induced by PEITC.
Akt is a serine–threonine kinase intimately involved in the
regulation of cell survival.20 It is activated by recruitment to the
cell membrane through the actions of PI3K, which in turn is
regulated by the PTEN phosphatase,21 mutations of which are
among the most commonly encountered in human cancers.22
Akt is involved in activation/phosphorylation of numerous down-
stream targets implicated in the modulation of diverse pathways
governing cell survival decisions, including those associated with
glycogen synthase kinase (GSK),23 m-TOR/p70rsk,24 and NF-
kB,25 among others. Most notably, PEITC exposure resulted in
diminished, rather than increased, Akt phosphorylation. Although
it would be tempting to attribute this phenomenon to PTEN
activation, the fact thatU937 cells do not expresswild-typePTEN
argueagainst this notion.26 Amore likely possibility is that PEITC,
through a mechanism yet to be elucidated, blocks the actions of
PI3K. The finding that LY29004, an inhibitor of PI3K, enhanced
the lethality of PEITC by blocking the activation of Akt and one or
more of its downstream targets (i.e., Mcl-1) is potentially
consistent with this concept.
In fact, the caspase-dependent downregulation of Akt is a
well-described phenomenon.27 Our present results indicate
that PEITC induces apoptosis by activating both caspase-8
and -9, along with caspase-3, raising the possibility that Akt
inactivationmight represent a consequence of engagement of
the caspase cascade. In this study, co-treatment of U937 cells
with the pan-caspase inhibitor Z-VAD-FMK, which abrogated
PEITC-induced activation of caspases (i.e., caspase-3, -8,
and -9) and apoptosis, failed to prevent Akt inactivation,
arguing strongly that factors other than caspase-mediated
events are involved in this phenomenon.
The bulk of evidence suggests that in human leukemia
cells, PEITC-induced Akt inactivation has a critical functional
role in mediating PEITC lethality. Significantly, enforced
activation of Akt and prevention of PEITC-induced Akt
downregulation largely reversed the lethal consequences of
PEITC exposure, including caspase activation, PARP clea-
vage, and apoptosis. It is worth noting that PEITC exposure
resulted in the downregulation of Mcl-1, an antiapoptotic
protein that may play a particularly important role in regulating
apoptosis in malignant hematopoietic cells.28 It has been
reported that the antiapoptotic gene Mcl-1 is upregulated by
the PI3K/Akt signaling pathway,29 and downregulation of Mcl-1
by inhibition of PI3K/Akt pathway is required for cell death.30
The finding that enforced activation of Akt largely blocked
PEITC-mediated downregulation of Mcl-1 may significantly
contribute to PEITC-mediated lethality.
Induction of caspase activation and apoptosis by PEITC
was also associated with the activation of the stress-related
JNK pathway. JNK belongs to the superfamily of MAP kinases
that are involved in the regulation of cell proliferation,
differentiation, and apoptosis.31 The critical role of JNK has
been shown in the lethal effects of diverse cytotoxic stimuli,
including ceramide,32 Fas ligand,33 UV,34 among others. The
finding that pharmacological and genetic interruption of the
JNK pathway attenuated PEITC-mediated lethality indicates
that stress pathways have a critical functional role in apoptosis
induction by this agent. Interestingly, co-administration with
PI3K inhibitor LY294002, which potentiate inactivation of Akt,
enhanced JNK activation and apoptosis induced by PEITC.
Furthermore, enforced activation of Akt not only blocked
PEITC-mediated caspase activation and apoptosis, but also
prevented the striking increase in JNK activation, raising the
possibility that one of the mechanisms by which Akt protects
cells from PEITC lethality is by opposing JNK activation. This
phenomenon might be explained by the following lines of
evidence. Firstly, ASK-1, the protein that activates JNK, is a
target of Akt inhibitory phosphorylation. Phosphorylation by
Akt inhibited JNK activity, which is mediated by ASK1,
providing the direct link between Akt and JNK.20 Secondly,
the interaction between Akt and JIP1 inhibited JIP1-mediated
potentiation of JNK activity by decreasing JIP1 binding to
specific JNK pathway kinases, suggesting that Akt interaction
with JIP1 acts as a negative switch for JNK activation.35
Previous studies have shown that PEITC markedly inhibits
tumor growth of human prostate and ovarian xenografts through
the induction of apoptosis.11,12,36,37 Little is known, however,
about inhibitory effects of PEITC on tumor growth of human
leukemia xenograft model. The results from in vivo studies have
shown that PEITC exhibits significant inhibitory effects on the
growth of U937 leukemia tumor xenograft. To understand
whether the apoptotic mechanism in vitro is identical to those
in vivo, we next examined apoptosis in tumor specimens
obtained from control and PEITC-treated animals using TUNEL
staining. The increase of TUNEL-positive cells was detected in
thePEITC-treated group comparedwith the control group,which
provides the apoptotic evidence in PEITC-treated U937
xenograft mice. This is the first report that describes an effective
extrapolation of the in vitro apoptosis-inducing effects of PEITC
on the leukemia cells to the in vivo situation. We also found that
administration of PEITC resulted in marked increase in
activation/cleavage of caspase-3 and PARP in tissue sections
of U937 tumor xenograft, further confirming the apoptotic
mechanism observed in vivo. To dissect the possible mechan-
isms in which the apoptotic signaling was triggered, we also
examined the expression levels of phospho-Akt, phospho-JNK,
and Mcl-1 in tissue sections of U937 xenograft tumor using
immunohistochemistry analysis. Our results suggest that
suppression of the p-Akt and Mcl-1 and upregulation of p-JNK
were closely correlated with the reduction of U937 tumor
xenografts. These results are consistent with the in vitro data.
In addition, the lack of toxicity in amousemodel points to PEITC
as a potential candidate for chemopreventive and chemother-
apeutic use. These data suggest that PEITC can be a possible
anticancer agent in the treatment of leukemia and possibly other
hematological malignancies.
In summary, these findings indicate that PEITC effectively
induces cell death in human leukemia cells, including primary
leukemia blasts, as well as in leukemia xenografts. This effect
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occurs in association with the inactivation of Akt, activation of
JNK, as well as downregulation of Mcl-1, such findings could
have chemopreventive or chemotherapeutic implications.
Materials and Methods
Cell lines. U937, HL-60, and Jurkat cells were purchased from American Type
Culture Collection (ATCC, Manassas, VA, USA) and maintained in RPMI 1640
medium containing 10% fetal bovine serum (FBS). The Akt-CA, which is an
Myc-tagged myr-Akt, and the Akt-DN were kindly provided by Dr. Richard Roth
(Stanford University, School of Medicine, Stanford, CA, USA), and were subcloned
into the pcDNA3.1. U937 cells were stably transfected with Akt-CA and Akt-DN
using the Amaxa nucleofector (Koeln, Germany) as recommended by the
manufacturer. Stable single-cell clones were selected in the presence of 400 mg/
ml of geneticin. Thereafter, the expression of Akt from each cell clone was analyzed
by western blot analysis.
Peripheral blood samples for the in vitro studies were obtained from 17 patients
with newly diagnosed or recurrent AML after informed consent. Approval was
obtained from the Southwest Hospital (Chongqing, China) institutional review board
for these studies. AML blasts were isolated by density gradient centrifugation over
Histopaque-1077 (Sigma Diagnostics, St. Louis, MO, USA) at 400 g for 38min.
Isolated mononuclear cells were washed and assayed for total number and viability
using Trypan blue exclusion. Blasts were suspended at 8 105/ml and incubated in
RPMI 1640 medium containing 10% FBS in 24-well plates. Fresh normal peripheral
blood mononuclear cells were purchased from Allcells (Emeryvill, CA, USA). After
washing and enumerating, cells were suspended at 8 105/ml before treatment.
Reagents and antibodies. PEITC was purchased from LKT Laboratories
(St. Paul, NM, USA). LY294002, SP600125, and Z-VAD-FMK were purchased from
EMD Biosciences (La Jolla, CA, USA). Antibodies against Akt, JNK, phospho-JNK,
and b-actin were from Santa Cruz Biotechnology (Santa Cruz, CA, USA); cleaved
caspase-3, cleaved caspase-9, phospho-Akt (Ser473), and Bcl-xL were from Cell
Signaling Technology (Beverly, MA, USA); XIAP, Mcl-1, Bax, and Bad were from
BD PharMingen; PARP was from Biomol (Plymouth Meeting, PA, USA); caspase-8 was
from Alexis (Carlsbad, CA, USA) and Bcl-2 was from Dako (Carpinteria, CA, USA).
RNA interference and transfection. U937 cells (1.5 106) were
transfected with 1 mg JNK1-annealed dsRNAi oligonucleotide 50-CGUGGGAU
UUAUGGUCUGUGTT-30/30-TTGCACCUAAAUACCAGACAC-50 (Orbigen, San
Diego, CA, USA) using the Amaxa nucleofectort (Koeln, Germany) as
recommended by the manufacturer. After incubation at 371C for 24 h, transfected
cells were treated with PEITC, and subjected to determination of apoptosis and JNK
expression using Annexin V/PI and flow cytometry and western blot analysis as
described below.
Apoptosis. The extent of apoptosis in leukemia cells was evaluated by flow
cytometric analysis using FITC-conjugated Annexin V/propidium iodide (BD
PharMingen) staining as per the manufacturer’s instructions as described
previously.38 Both early apoptotic (Annexin V-positive, PI-negative) and late
apoptotic (Annexin V-positive and PI-positive) cells were included in cell death
determinations.
Western blot analysis. The total cellular samples were washed twice with
ice-cold PBS and lysed in 1NuPAGE LDS sample buffer supplemented with
50mM dithiothreitol. The protein concentration was determined using Coomassie
Protein Assay Reagent (Pierce, Rockford, IL, USA). In total, 30 mg of sample
proteins were separated by SDS-PAGE and transferred to nitrocellulose membrane.
Membranes were blocked with 5% fat-free dry milk in 1 Tris-buffered saline (TBS)
and incubated with antibodies. Protein bands were detected by incubating with
horseradish peroxidase-conjugated antibodies (Kirkegaard and Perry Laboratories,
Gaithersburg, MD, USA) and visualized with enhanced chemiluminescence reagent
(Perkin-Elmer, Boston, MA, USA).
Xenograft. NOD/SCID mice (5 weeks old) were purchased from Vital River
Laboratories (Beijing, China). All animal studies were conducted according to
protocols approved by the Institutional Animal Care and Use Committee of the
University. U937 cells (2 106/0.2 ml per mouse) were suspended in sterile PBS
and injected subcutaneously into the right flank of the mice. Mice were randomized
into two groups of 10 mice per group. At 3 days after tumor inoculation, the
treatment group received PEITC (50mg/kg, i.p. for 20 days). The control group
received an equal volume of solvent control. Tumor size and body weight were
measured after treatment at various time intervals throughout the study. At the
termination of the experiment, mice were killed at 24 h after the last administration of
compound. The tumors were excised and weighed. Tumors were collected at
selected times and fixed in paraformaldehyde. Paraffin-embedded tissues were
sectioned and processed for H&E, TUNEL, and immunohistochemical staining.
TUNEL. The apoptotic cells in tissue samples were detected using an In Situ
Cell Death Detection kit (Roche, Mannheim, Germany) according to the
manufacturer’s manual. After deparaffinization and permeabilization, the tissue
sections were incubated in proteinase K for 15min at room temperature. The
sections were then incubated with the TUNEL reaction mixture that contains
terminal deoxynucleotidyl transferase and fluorescein-dUTP at 371C for 1 h. After
washing three times with PBS, the sections were incubated with the Converter-
POD, which contains anti-fluorescein antibody conjugated with horse-radish
peroxidase (POD) at room temperature for 30min. After washing three times with
PBS, the sections were incubated with 0.05% 3-30-diaminobenzidine
tetrahydrochloride and analyzed under light microscope.
Histological and immunohistochemical evaluation. At the
termination of experiments, tumor tissues from representative mice were
sectioned, embedded in paraffin, and stained with H&E for histopathological
evaluation. For immunohistochemical analysis, tissue sections 4mm in thickness
were dewaxed and rehydrated in xylene and graded alcohols. Antigen retrieval was
performed with 0.01M citrate buffer at pH 6.0 for 20min in a 951C water bath. Slides
were allowed to cool for another 20min, followed by sequential rinsing in PBS and
TBS-T buffer. Endogenous peroxidase activity was quenched by incubation in
TBS-T containing 3% hydrogen peroxide. Each incubation step was carried out at
room temperature and was followed by three sequential washes (5 min each) in
TBS-T. After blocking with 10% goat serum for 1 h, sections were incubated with
primary antibodies, washed three times in PBS, incubated with biotinylated
secondary antibody for 1 h, followed by incubation with a streptavidin–peroxidase
complex for another 1 h. After three additional washes in PBS, diaminobenzidine
working solution was applied. Finally, the slides were counterstained in hematoxylin.
Statistical analysis. Tumor volumes, body weights, and percentage of
apoptotic cells were represented as mean±S.D. The statistical significance of the
difference between control and PEITC-treated groups was evaluated using
Student’s t-test. Po0.05 or 0.01 were considered significant.
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